A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)

Summary

This is a Phase 2 randomized, double-blind, placebo-controlled study with a total duration of 32 weeks from Screening to End-of-Study (EOS) Visit. Approximately 180 participants are planned to be enrolled. The number of participants can be extended to maximally 220 to account for dropouts during the study.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Active Rheumatoid Arthritis

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 to 75 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Elevara Medicines Limited

Last updated on ClinicalTrials.gov

July 20, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites